List of Altreno drug patents

Altreno is owned by Dow Pharm.

Altreno contains Tretinoin.

Altreno has a total of 2 drug patents out of which 0 drug patents have expired.

Altreno was authorised for market use on 23 August, 2018.

Altreno is available in lotion;topical dosage forms.

Altreno can be used as topical treatment of acne vulgaris in patients 9 years of age and older.

The generics of Altreno are possible to be released after 22 August, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653656 DOW PHARM Topical pharmaceutical compositions for treating skin conditions
Aug, 2038

(15 years from now)

US11324710 DOW PHARM Topical pharmaceutical compositions for treating skin conditions
Aug, 2038

(15 years from now)

Drugs and Companies using TRETINOIN ingredient

Market Authorisation Date: 23 August, 2018

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

ALTRENO family patents

5

United States

1

Argentina

1

Brazil

1

Canada

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic